Over 2.5 million people in the United Kingdom have begun using GLP-1 receptor agonists for weight management. This surge in medication use coincides with a sharp decline in the number of patients undergoing bariatric surgery.
The 67% plunge in gastric sleeve procedures
The United Kingdom is witnessing a fundamental change in how obesity is managed, as injectable GLP-1 therapies replace traditional surgical interventions. According to the report, bariatric surgery rates have seen a dramatic downturn, with gastric sleeve operations dropping by 67% between 2023 and 2025. This trend is even more pronounced in gastric bypass procedures, which have fallen by 79% during that same window.
This move toward pharmacotherapy reflects a broader medical shift toward non-invasive weight management. However, while these drugs are becoming the new standard for many,the decline in surgical volume suggests a potential loss of long-term, permanent options for those with the most severe cases of obesity.
Estrogen's role in the 20% weight loss target
While clinical trials often show spectacular results, real-world application of GLP-1 drugs is not universal. A 2024 study published in JAMA highlighted that patients using tirzepatide, the active ingredient in Mounjaro, lost an average of 20% of their body weight over nine months.. Yet, the report notes that between 10% and 15% of patients experience minimal benefits or suffer from side effects like diarrhea and nausea.
New research published in the journal Nature suggests that biological markers may explain why some patients thrive while others struggle. Specifically,the presence of estrogen appears to enhance the efficacy of these agents, meaning pre-menopausal women or those on hormone replacement therapy may see better results than men or post-menopausal women. This biological variability raises questions about whether a "one size fits all" approach to prescribing these drugs is truly effective.
Dr. Ahmed Ahmed and the 4.2 million underserved patients
The gap between those who need surgical intervention and those who receive it is widening significantly. Dr. Ahmed Ahmed, the clinical lead for bariatric surgery at Imperial College Healthcare NHS Trust, points out that only about 1% of the 4.2 million eligible patients in the UK actually undergo surgery. This is a stark contrast to the growing number of people utilizing injectable medications.
The National Health Service (NHS) is also seeing a contraction in surgical volume, performing only 5,000 to 6,000 bariatric operations annually. This is a notable decrease from the 8,000 procedures performed a decade ago.. As the popularity of GLP-1s grows, medical professionals are concerned that the surgical infrastructure and expertise required for permanent weight loss may be sidelined.
The economic tension between daily injections and one-time surgery
Policymakers are currently caught in a difficult decision regarding how to allocate limited healthcare resources. While GLP-1 injections offer immediate, non-invasive relief, they often require continuous, long-term use that can be expensive for patients paying out of pocket. In contrast, bariatric surgery offers a permanent alteration to the digestive system, which could potentially offer the NHS a more cost-effective solution over a patient's lifetime.
There are still significant unknowns regarding the long-term economic impact of this shift. It remains unclear how the NHS will balance the rising demand for novel pharmacotherapies against the proven, durable results of surgery. Furthermore, the role of cheaper oral medications like Mysimba remains a question mark in the broader strategy for managing mild obesity.
Comments 0